Showing results (91-100 of 105) with videos related to
Sort By:
Pageof 11
Oncotarget|October 29, 2013
Alterations of immune response of Non-Small Cell Lung Cancer with AzacytidineJohn Wrangle, Wei Wang, Alexander Koch, et al.Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.Journal for Immunotherapy of Cancer|October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumabNicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.JCO Precision Oncology|November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker SummitDaniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public WorkshopKristen L Mueller, Marc R Theoret, Steven J Lemery, et al.Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerScott N Gettinger, Leora Horn, Leena Gandhi, et al.The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.Pageof 11